NCT04613596 2026-03-18Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7Mirati Therapeutics Inc.Phase 2/3 Recruiting806 enrolled